STAAR Surgical Q1 2026: Early Signs Of A Durable Turnaround
STAAR Surgical Company delivered a robust 1Q26 beat, with revenue up 119% YoY to $93.5M and a swing…
seekingalpha.com
VCEL(VCEL)
VCEL
Next earnings: Jul 30, 2026 · Before open
Signal
Leaning Bearish1↓
PRICE
Prev Close
33.14
Open
32.79
Day Range32.25 – 33.39
32.25
33.39
52W Range28.95 – 45.97
28.95
45.97
24% of range
VOLUME & SIZE
Avg Volume
648.9K
FUNDAMENTALS
P/E Ratio
76.8x
Premium valuation
EPS (TTM)
—
Div Yield
No dividend
Beta
1.53
High vol
Performance
1D↑
+0.91%5D
-4.61%1M
-5.69%3M
-7.84%6M
-16.86%YTD
-7.97%1Y↓
-21.65%Best: 1D (+0.91%)Worst: 1Y (-21.65%)
Quick Read
Trend—Insufficient MA data
Momentum
BULLISH
revenue +22% YoY · 75% gross marginValuation
EXPENSIVE
P/E 77x vs ~20x sectorHealth
STRONG
CR 5.2 · FCF $1.14/shBullish
Key MetricsTTM
Market Cap$1.69B
Revenue TTM$292.09M
Net Income TTM$21.46M
Free Cash Flow$57.81M
Gross Margin74.8%
Net Margin7.3%
Operating Margin5.4%
Return on Equity6.4%
Return on Assets4.4%
Debt / Equity0.27
Current Ratio5.18
EPS TTM$0.42
Alpha SignalsView Intelligence →
Intelligence analysis not yet available for this stock. Full AI-powered analysis may be available on the intelligence page.
Health Radar
4 strong2 concern
65/100Liquidity
5.18Strong
Leverage
0.27Strong
Coverage
24.8xStrong
ROE
6.4%Concern
ROIC
3.4%Concern
Cash
$100MStrong
ANALYST COVERAGE13 analysts
BUY
▲ +39.3%upside to target
L $42.00
Med $46.00consensus
H $70.00Stock Health
Composite Score
3 of 5 signals bullish
5/10
Technicals
●
✗RSI RangeRSI 32 — Bearish momentum
Volume
●
✗Volume FlowDistribution — institutional selling
Fundamentals
●
✓Last EarningsBeat estimates
●
✓Analyst ConsensusBuy
●
✓LiquidityCurrent Ratio 5.18 — healthy liquidity
Upcoming Events
EEarnings ReportMay 17, 2026
Tomorrow
DEx-Dividend DateAug 14, 2026
In 90 days
PDividend PaymentAug 31, 2026
In 107 days
FinancialsFull statements →
Technicals
Technical SetupBEARISH
Technicals →Trend
→ PullbackGolden Cross · 50D leads 200D by 22.5%
-11.3% vs SMA 50 · +8.7% vs SMA 200
Momentum
RSI32.4Momentum fading
MACD-1.24Below zero — bearish pulse · compressing
Market Position
Price Levels
52W High
$45.97+39.2%
EMA 50
$36.08+9.2%
Current
$33.03
EMA 200
$30.42-7.9%
52W Low
$28.95-12.4%
52-Week RangeNear 52-week low
$28.9524th %ile$45.97
Squeeze SetupVolume-based
Distribution PressureDistribution pattern detected. More selling days than accumulation over the past 20 sessions. Not a conducive environment for a squeeze.
20-Day Money Flow
Acc days:1
Dist days:7
Edge:+6 dist
Volume Context
Avg Vol (50D)686K
Recent Vol (5D)
589K-14%
Based on volume distribution analysis. Direct short interest data (short float %, days to cover) is not available in current data sources.
Earnings & Analysts
ANALYST ESTIMATES
Consensus of 6 analysts
Analyst revisions:EPS↓ Revised DownRevenue↓ Revised Down
Analyst consensus estimates · Actuals replace estimates as reported
| Year | Revenue Est. | Rev Gth | EPS Est. | EPS Gth | Range | Analysts |
|---|---|---|---|---|---|---|
FY2025 | $274.4M $273.9M–$275.3M | — | $0.27 | — | ±39% | High5 |
FY2026(current) | $332.2M $327.3M–$337.1M | ▲ +21.1% | $0.47 | ▲ +77.3% | ±19% | High6 |
FY2027 | $388.6M $379.9M–$397.4M | ▲ +17.0% | $0.88 | ▲ +85.6% | ±17% | High6 |
Range confidence:Tight (high)ModerateWide (low)
Earnings HistoryVCEL
Last 8Q
+77.8%avg beat
Beat 5 of 8 quartersMissed 1↑ Estimates rising—
Q3'24
+60%
Q4'24
+23%
Q1'25
-156%
Q2'25
+75%
Q3'25
+600%
Q4'25
—
Q1'26
+20%
Q2'26
Beat
Miss
Estimate
Deeper color = bigger beat/miss
* Negative EPS shown at reduced heightInsider Activity
SEC Filings →0 Buys/6 SellsNet Selling
NET SELLERS$0 bought · $948K sold · 30d window
Mclaughlin Kevin FDir
$115K
May 13
SELL
Mclaughlin Kevin FDir
$115K
May 13
SELL
Wotton Paul KDir
$83K
May 11
SELL
Wotton Paul KDir
$245K
May 11
SELL
Mara Joseph Anthony…CFO
$203K
May 7
SELL
Siegal JonathanPrincipal Acco…
$130K
May 6
SELL
Financials
INSTITUTIONAL OWNERSHIP
1
BlackRock, Inc.
7.8M▲2
STATE STREET CORP
3.2M▼3
Soleus Capital Management, L.P.
2.5M▲4
Conestoga Capital Advisors, LLC
2.5M▲5
WILLIAM BLAIR INVESTMENT MANAGEMENT, LLC
1.8M▼6
BNP Paribas Asset Management Holding S.A.
1.7M▲7
GENEVA CAPITAL MANAGEMENT LLC
1.6M▼8
GW&K Investment Management, LLC
1.6M▲News & Activity
VCEL News
20 articles · 4h ago
Snail returns to profitability in Q1 as revenue surges - ICYMI
proactiveinvestors.com
kneat.com Q1 Earnings Call Highlights
marketbeat.com
Neo Performance Materials Q1 Earnings Call Highlights
marketbeat.com
Northland Power Q1 Earnings Call Highlights
marketbeat.com
Terreno Realty Corporation: This Coastal Industrial REIT Is A Buy
seekingalpha.com
Users turn to jailbreaking their older Kindles as Amazon ends support
techcrunch.com
Why Investors Need to Take Advantage of These 2 Retail and Wholesale Stocks Now
zacks.com
Value, Quality, Momentum, And Lower Volatility In One Emerging Markets Fund
247wallst.com
Louisiana-Pacific: A Good Siding Business Offset By A Weak OSB Market
seekingalpha.com
Tesla raises prices of Model Y cars in the US
reuters.com
A Gemini-Fueled Fitbit Could Be the Muscle That Google's Smart Glasses Need
cnet.com
How MLB's and T-Mobile's ABS Challenge System Corrects Strike Calls in Seconds
cnet.com
ArriVent BioPharma: Stronger Balance Sheet And Pipeline Upside Reinforce Our Bull Case
seekingalpha.com
A Major Catalyst Is Emerging For BDCs That The Market Is Completely Missing
seekingalpha.com
Bill Gates Just Did the Unthinkable — He Sold Every Last Share of Microsoft Stock
247wallst.com
Let's Talk About Your Big “But”
etftrends.com
Global oil stockpiles could hit record lows if Strait of Hormuz remains closed
cnbc.com
SPHQ Outpaced JQUA by 500 Basis Points Over Five Years Despite Being the Riskier Trade
247wallst.com
Berkshire's new CEO overhauls portfolio, dumping a slate of stocks
cnbc.com
About
about vericel founded in 1989, vericel (formerly aastrom biosciences), is dedicated to the development of patient-specific expanded cellular therapies for use in the treatment of patients with severe diseases and conditions. the company markets two cell therapy products in the united states, carticel® (autologous cultured chondrocytes), an autologous chondrocyte implant for the treatment of cartilage defects in the knee and epicel® (cultured epidermal autografts), a permanent skin replacement for the treatment of patients with deep dermal or full thickness burns greater than or equal to 30% of total body surface area. vericel is also developing maci, a third-generation autologous chondrocyte implant for the treatment of cartilage defects in the knee, and ixmyelocel-t, a patient specific multicellular therapy for the treatment of advanced heart failure due to ischemic dilated cardiomyopathy (dcm). to fulfill vericel’s mission of helping people with severe diseases and conditions rea
Industry
Research and Development in Biotechnology (except Nanobiotechnology)
CEO
Dominick Colangelo
Website
Dominick C. ColangeloChief Executive Officer, President & Director
Doug KennedySenior Vice President of Operations
Eric BurnsVice President of Finance & Investor Relations
Peers— Health Care(7 companies)
Screen sector →| Symbol | Price | Day % | Mkt Cap↓ | P/E | Rev Grw | Margin | ELO |
|---|---|---|---|---|---|---|---|
VCEL◀ | $33.03 | +0.91% | $1.7B | — | +1645.5% | 597.9% | 1500 |
| $66.13 | -5.07% | $13.0B | — | +12626.1% | -14525.8% | 1500 | |
| $94.92 | -3.79% | $12.6B | — | +3288.2% | -4239.0% | 1500 | |
| $523.69 | -3.00% | $12.1B | — | +43205.3% | -3008.0% | 1500 | |
| $227.72 | -1.30% | $11.7B | — | +6554.5% | -2868.8% | 1500 | |
| $57.90 | -0.86% | $11.2B | 50.3 | +1459.3% | 147.7% | 1500 | |
| $76.67 | -3.79% | $10.8B | — | +2325815.3% | -19.7% | 1500 | |
| Sector avg | — | -2.41% | — | 50.3 | +342084.9% | -3416.5% | 1500 |